Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. (Q53835279)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. (English)

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

phase III clinical trial

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

Caroline Robert

19

object named as

Caroline Robert

0 references

object named as

Ana Arance

4

0 references

Dirk Schadendorf

8

object named as

Dirk Schadendorf

1 reference

Europe PubMed Central

20 May 2018

20

object named as

Keith T Flaherty

1 reference

Europe PubMed Central

20 May 2018

Paolo Antonio Ascierto

2

object named as

Paolo A Ascierto

1 reference

Europe PubMed Central

20 May 2018

Reinhard Dummer

1

object named as

Reinhard Dummer

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

10

object named as

Ralf Gutzmer

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

15

object named as

Carmen Loquai

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

7

object named as

Claus Garbe

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

Laure A Moutouh-de Parseval

16

object named as

Laure A Moutouh-de Parseval

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

Caroline Dutriaux

12

object named as

Caroline Dutriaux

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

author name string

Helen J Gogas

3

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

Mario Mandala

5

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

Gabriella Liszkay

6

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

Ivana Krajsova

9

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

Vanna Chiarion-Sileni

11

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

Jan Willem B de Groot

13

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

Naoya Yamazaki

14

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

Michael D Pickard

17

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

Victor Sandor

18

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

Caroline Robert

19

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

publication date

21 March 2018

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

Lancet Oncology Commission

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

19

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

5

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

603-615

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

New strategies in melanoma: entering the era of combinatorial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved overall survival in melanoma with combined dabrafenib and trametinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved survival with MEK inhibition in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Ultraviolet A and photosensitivity during vemurafenib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(18)30142-6

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

release_dhrpl2oydvcsrg66kxqlmxtdgq

1 reference

https://api.fatcat.wiki/v0/release/dhrpl2oydvcsrg66kxqlmxtdgq

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/MED/29573941

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53835279&oldid=2119060211"